Peptides
Body
Composition
Weight
Management
Recovery & Repair
Reproductive Health
& Tanning
Longevity
& Skin Care
Cognitive
Enhancement
Tesamorelin
Tirzepatide
TB-500
Kisspeptin
GHK-Cu
Selank
Ipamorelin
Semaglutide
BPC-157
Melanotan 2
Epithalon
Semax
CJC-1295
Retatrutide
NAD+
PT-141
DSIP
MOTS-C
5-Amino-1MQ
FRAG 176-191
Hexarelin
MK-677

Retatrutide: The Complete Guide to Dosage, Benefits, and Research in 2024

1. Retatrutide Dosage Chart | Quick Breakdown

Purpose Dosage Frequency Administration
Obesity Treatment 1-12 mg Once weekly Subcutaneous injection
Type 2 Diabetes 0.5-12 mg Once weekly Subcutaneous injection
Research 1-12 mg Once weekly Subcutaneous injection

2. What is Retatrutide?

Retatrutide (LY3437943) is a novel triple agonist peptide developed by Eli Lilly and Company. Key points:

  • Activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors

  • Molecular formula: C223H343F3N46O70

  • Molecular weight: 4845.444 g/mol

  • Synthetic peptide with 30 amino acids and a fatty acid moiety

  • Designed for the treatment of obesity and type 2 diabetes

Table of Contents

3. Retatrutide Mechanism of Action

Retatrutide works through several mechanisms:

  1. Activates GLP-1 receptors, promoting insulin secretion and reducing glucagon release

  2. Stimulates GIP receptors, enhancing insulin sensitivity and glucose uptake

  3. Activates glucagon receptors, potentially increasing energy expenditure

  4. Slows gastric emptying, promoting satiety

  5. Reduces food intake through central nervous system effects

  6. Enhances beta-cell function and insulin sensitivity

  7. Promotes weight loss through multiple pathways

4. Research Applications and Potential Benefits of Retatrutide

Retatrutide and Obesity

  • Significant weight loss in clinical trials (up to 24% of body weight in 48 weeks)

  • Reduction in waist circumference

  • Potential for long-term weight management

Retatrutide and Type 2 Diabetes

  • Improves glycemic control (HbA1c reduction)

  • Enhances insulin sensitivity

  • Potential to reduce diabetes-related complications

PT-141 and Sexual Arousal

  • Enhances sexual arousal in both men and women

  • Potential treatment for generalized arousal disorders

Retatrutide and Cardiovascular Health

  • Reduces blood pressure

  • Improves lipid profiles

  • Potential cardioprotective effects

Retatrutide and Liver Health

  • Reduces liver fat content in patients with non-alcoholic fatty liver disease (NAFLD)

  • Potential to prevent progression to non-alcoholic steatohepatitis (NASH)

5. Retatrutide Dosage Guide

Dosing Retatrutide for Obesity Treatment

  • Starting dose: 1 mg once weekly

  • Dose escalation: Increase by 2-4 mg every 4 weeks

  • Maximum dose: 12 mg once weekly

Dosing Retatrutide for Type 2 Diabetes

  • Starting dose: 0.5-1 mg once weekly

  • Dose escalation: Increase based on glycemic response and tolerability

  • Maximum dose: 12 mg once weekly

Dosing Retatrutide for Research

  • Dose range: 1-12 mg once weekly

  • Specific dosing depends on research protocol and objectives

6. How to Mix and Administer Retatrutide

Retatrutide is typically supplied as a pre-filled, single-dose pen:

  1. Remove pen from refrigerator 30 minutes before injection

  2. Clean injection site with alcohol swab

  3. Remove pen cap and inject as directed

  4. Hold needle in place for 5 seconds after injection

  5. Dispose of used pen in a sharps container

7. Retatrutide Administration Methods

Subcutaneous Injection

  • Most common and only approved method

  • Inject into abdomen, thigh, or upper arm

  • Rotate injection sites weekly

8. Retatrutide Combinations and Interactions

Retatrutide + Metformin

  • Potential for enhanced glycemic control in type 2 diabetes

Retatrutide + SGLT2 Inhibitors

  • Possible additive effects on weight loss and glycemic control

Always consult with a healthcare professional before combining medications.

9. Where to Buy Retatrutide Online | 2024 Edition

As of 2024, retatrutide is not yet approved for commercial use. It is currently only available through clinical trials or research programs.

10. Is Retatrutide Safe?

Based on clinical trials, retatrutide appears to have a safety profile similar to other GLP-1 receptor agonists. Common side effects include:

  • Nausea

  • Vomiting

  • Diarrhea

  • Constipation

  • Abdominal pain

  • Headache

Long-term safety data is still being collected through ongoing clinical trials.

11. Is Retatrutide Legal?

  • Not yet approved by the FDA or other regulatory agencies for human use

  • Currently in Phase 3 clinical trials

  • Legal status may change upon completion of trials and regulatory review

12. Retatrutide Storage and Handling

  • Store in refrigerator (2°C to 8°C or 36°F to 46°F)

  • Do not freeze

  • Protect from light

  • Can be stored at room temperature for up to 14 days

  • Keep out of reach of children

13. Frequently Asked Questions (FAQ)

How long does it take to see effects from retatrutide?

 In clinical trials, significant weight loss was observed within 4-8 weeks, with maximum effects seen after 24-48 weeks of treatment.

Can retatrutide be used for weight loss in non-diabetic individuals?

Clinical trials are investigating its use in individuals with obesity, with or without diabetes. Approval for this indication will depend on trial results and regulatory decisions.

How does retatrutide compare to other weight loss medications?

Early data suggests retatrutide may be more effective than currently approved GLP-1 receptor agonists, but head-to-head trials are needed for direct comparisons.

14. Retatrutide Dosage | Final Verdict

Retatrutide shows significant promise as a treatment for obesity and type 2 diabetes, with potential benefits extending to cardiovascular and liver health. Its unique triple agonist mechanism offers the possibility of greater efficacy compared to existing treatments. The typical dosage range of 1-12 mg administered once weekly appears effective for most applications, with dose escalation protocols allowing for individualized treatment.However, as retatrutide is still in clinical development, its use should be approached cautiously and only within the context of approved clinical trials or research programs. Long-term safety and efficacy data are still being collected, and regulatory approval is pending. The potential of retatrutide in obesity, diabetes, and related conditions warrants continued investigation and close monitoring of ongoing clinical trials.

15. References

  1. Rosenstock J, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 402(10396), 121-134.

  2. Jastreboff AM, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med, 389(3), 228-241.

  3. Sanyal AJ, et al. (2023). Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults with Overweight or Obesity. N Engl J Med, 389(22), 2067-2080.

  4. Lilly. (2023). Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight. [Press Release]

  5. Eli Lilly and Company. (2023). A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes (TRIUMPH-3). ClinicalTrials.gov Identifier: NCT05647850.

Disclaimer

Peptideresearcher.com contains information about products intended for research and laboratory use only, unless otherwise explicitly stated. All content is for educational purposes and is not meant to substitute for professional medical advice. Peptideresearcher.com strives to ensure that all information presented is accurate and complies with national and international standards, but it is not guaranteed. The content provided is not intended to diagnose, treat, cure, or prevent any disease or condition.

Peptideresearcher.com does not offer medical diagnoses or prescriptions. Any product information shared is solely for research purposes and should be used by qualified professionals only. We advise all users to consult with a healthcare professional before using any peptides, supplements, or medications mentioned on this site. All opinions expressed are those of the individual authors and may not reflect the opinions of Peptideresearcher.com.

Copyright 2024 - Peptide Researcher

Your access to Peptideresearcher.com is subject to our Terms of Use